A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
PHASE1CompletedINTERVENTIONAL
Enrollment
100
Participants
Timeline
Start Date
January 31, 2015
Primary Completion Date
August 31, 2015
Study Completion Date
August 31, 2015
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG
Rolapitant
Trial Locations (1)
21225
Parexel, Baltimore
All Listed Sponsors
lead
Tesaro, Inc.
INDUSTRY
NCT02382666 - A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers | Biotech Hunter | Biotech Hunter